Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Biogen(BIIB) CNBC·2024-02-13 20:03
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category. Biogen booked sales of 1.17 billion as the therapies face competition from cheaper generics. The results come as the ...